Two New Solutions from Hemex Health Empower More Clinicians and Health Workers to Test for Iron Deficiency Anaemia and Sickle Cell Disease
November 14, 2024 08:00 ET
|
Hemex Health
NAGPUR, India, Nov. 14, 2024 (GLOBE NEWSWIRE) -- At the Haematocon 2024 conference in Nagpur, India, Hemex Health announced new product offerings for the Company’s Gazelle™ Diagnostic Device that...
Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease
October 07, 2024 05:00 ET
|
Hemex Health
In Brief: Findings from studies in Türkiye and Ghana presented at ASCAT 19th Annual Scientific Conference demonstrate that the Gazelle™ Hb Variant Test is an effective tool for accurate and...
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
June 20, 2024 08:00 ET
|
Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder
February 05, 2024 08:00 ET
|
Hemex Health
A clinical study demonstrated high accuracy for Hemex Health's beta thalassemia test. It is the only beta thal test for point of care.
California State Treasurer, Fiona Ma, and US-India cross-border association, AllianceIndus, congratulate Hemex Health for India partnerships that led to a breakthrough test for sickle cell disease
October 17, 2023 21:00 ET
|
Hemex Health
SAN FRANCISCO and PORTLAND, Ore., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemex Health, Inc., a medical device company based in Portland, Oregon and Mumbai, India, was honored today by AllianceIndus at...
Hemex Health Awarded $3M NIH Grant to Bring Gazelle Hb Variant Test for Sickle Cell Disease to US Market
March 27, 2023 08:00 ET
|
Hemex Health
PORTLAND, Ore., March 27, 2023 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostic device company focused on expanding healthcare access to underrepresented patient populations, announced it has...
Hemex Health and Mylab Discovery Solutions Launch Gazelle™ PathoCatch™ COVID-19 FIA Test
July 06, 2022 08:00 ET
|
Hemex Health
PORTLAND, Ore. and PUNE, India, July 06, 2022 (GLOBE NEWSWIRE) -- Mylab Discovery Solutions, India’s leading biotechnology company, and Portland, OR-based Hemex Health, a medical diagnostic device...
New Data to Be Presented at the 4th Global Congress on Sickle Cell Disease Will Spotlight High Accuracy from Hemex Health’s Gazelle™ Reader for Diagnosing Newborn Sickle Cell Disease, Beta Thalassemia and Monitoring Fetal Hemoglobin Levels
June 15, 2022 09:50 ET
|
Hemex Health
PORTLAND, Ore., June 15, 2022 (GLOBE NEWSWIRE) -- New clinical data from Hemex Health, a Portland, Oregon-based health-tech startup, will be spotlighted at the 4th Global Congress on Sickle Cell...
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET
|
Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
New Research Reveals Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for P. Vivax Malaria, Detected Challenging Types of Malaria, and Provided Affordable Sickle Cell Disease Detection
November 16, 2020 16:10 ET
|
Hemex Health
PORTLAND, Ore., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the...